(NASDAQ: LFCR) Lifecore Biomedical's forecast annual revenue growth rate of 11.1% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 121%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.27%.
Lifecore Biomedical's revenue in 2025 is $130,309,000.On average, 6 Wall Street analysts forecast LFCR's revenue for 2026 to be $4,996,568,418, with the lowest LFCR revenue forecast at $4,689,998,678, and the highest LFCR revenue forecast at $5,335,350,197. On average, 6 Wall Street analysts forecast LFCR's revenue for 2027 to be $5,544,543,317, with the lowest LFCR revenue forecast at $5,166,884,941, and the highest LFCR revenue forecast at $5,844,078,245.
In 2028, LFCR is forecast to generate $6,773,043,800 in revenue, with the lowest revenue forecast at $6,469,436,086 and the highest revenue forecast at $7,012,967,945.